@Article{ecn.2015.0365,
AUTHOR = {Kenan Izgi, Banu Iskender, Cagri Sakalar, Aslihan Arslanhan, Berkay Saraymen, Halit Canatan},
TITLE = {Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice},
JOURNAL = {European Cytokine Network},
VOLUME = {26},
YEAR = {2015},
NUMBER = {2},
PAGES = {46--56},
URL = {http://www.techscience.com/ECN/v26n2/65550},
ISSN = {1952-4005},
ABSTRACT = {Rationale: Organ- or tissue-specific antigens produced by normal tissue or by cancer cells could be
used in cancer immunotherapy, to target the tumor. In our previous study, we induced T-cell-mediated, bladder-specific
autoimmunity by targeting the bladder-specific protein Uroplakin 3A (UPK3A). UPK3A is a well-chosen
target for developing an autoimmune response against bladder cancer since the antigen is also expressed in bladder
tumors. To use this peptide, which was derived from the UPK3A protein in a bladder cancer vaccine study, it is
necessary to induce a strong immune response. In this study, we aimed to develop a robust immune response in
BALB/c mice using the well-characterized keyhole limpet hemocyanin (KLH)-conjugated peptide antigen (UPK3A
65-84) conjugated with an immunogenic carrier protein. In combination with the peptide, we used either Freund’s
complete adjuvant (CFA) or CpG (cytosine-phosphate-guanine oligonucleotides) as effective adjuvants in order to
overcome tumor tolerance. Objectives: The immune response evoked by UPK3A 65-84 peptide, using two different
adjuvants, was compared by detection of changes in the proliferative response of immune cells, in the cytokine
profile, and in the immune cell populations. Findings: We demonstrated that CpG, combined with KLH-UPK3A
65-84, promoted a more robust immune response, via induction of higher IL-2, IFN-γ, TNF-α, IL-17 production
and activation of more immune cells (CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, NK cells CD11b, CD45), than CFA and the KLH-UPK3A
65-84.Conclusion: CpG as an adjuvant combined with KLH-UPK3A 65-84 could be used in preclinical
models of bladder cancer for the development of cancer immunotherapy strategies.},
DOI = {10.1684/ecn.2015.0365}
}